Treatment for people with chronic insomnia

Anecdotally, cannabis, in its’ plant form, is commonly reported to be a useful sleep aid, but there are very few studies investigating the effects of a pharmaceutical-grade formulation. In this study, we will assess the effects of a single dose of an oral formulation containing tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:20 ratio (‘ETC120’) on sleep and next-day function in people with chronic insomnia disorder relative to a placebo.

This study involves 5 – 6 visits over a 2-month period.

If eligible, you will need to come to the Woolcock Institute of Medical Research in Glebe, Sydney, and stay in one of our sleep suites overnight on two occasions. We will measure various aspects of your sleep and cognition over a 24-hour period.

You will receive reimbursement for your time and, at no expense to you, study medication and study-related medical evaluations from a sleep doctor.

Bellberry Human Research Ethics approval number: 2018-04-284

You may qualify if you:

• live in Sydney, NSW,
• are 35 - 60 years of age,
• have chronic insomnia (persistent problems falling or staying asleep),
• are not a shift worker,
• are willing and able to complete two overnight sleep studies at the Woolcock Institute of Medical Research in Glebe, Sydney.

To get involved in the trial, click here to check your suitability at www.cansleepstudy.com 

For more information, please contact the trial coordinator (Anastasia Suraev):
Email: cansleep@woolcock.org.au 
Mobile: 0439 804 551